EGFR and cancer: Surprisingly, a suggested mechanism whereby cancer cells may become resistant to EFGR inhibitors is the maintenance of PI3K signaling [129], thus combining EGFR inhibitors with PX-866, a novel PI3K-disabling agent whose treatment has revealed a moderate tumor growth fall in the base of tongue and tonsil carcinomas [130].